[Parotitis and influenza: unusual association during 2017, in Santa Fe, Argentina]. / Parotiditis e influenza: inusual asociación durante 2017, en Santa Fe, Argentina.

BACKGROUND: Parotitis is an acute viral disease characterized by swelling and pain in one or both salivary glands, submaxillary or submental, fever, headache, muscle ache and/or fatigue. AIM: To investigate the occurrence of influenza virus infection in parotitis cases in a population of Santa Fe during 2017 and analyze clinical and epidemiological characteristics of the cases. METHODS: We studied patients with diagnosis of mumps without age restriction, who came for examination from week 26 to the network of clinicians forming the Sentinel Influenza Unit in Santa Fe. RESULTS: Between epidemiological weeks 26 and 44, 22 clinical parotitis cases we enrolled. The influenza virus was detected in 68.2%, influenza A (H3N2) 93%, and influenza B, 7%. The clinical signs of cases were mild, with an average swelling development of 5 days and no complications. 74% presented with influenza-like illness in tandem with parotitis. CONCLUSIONS: This study provides evidence that a proportion of children presenting with parotitis had influenza A(H3N2) virus infection. It is necessary to implement systematic surveillance of parotitis associated with influenza and differential diagnosis even in the absence of respiratory symptoms.

Parotiditis e influenza: inusual asociación durante 2017, en Santa Fe, Argentina / Parotitis and influenza: unusual association during 2017, in Santa Fe, Argentina

Resumen Introducción: La parotiditis es una enfermedad vírica aguda caracterizada por tumefacción y dolor en una o ambas glándulas salivales, submaxilar o submentoniana, fiebre, dolor de cabeza, dolor muscular y/o fatiga. Objetivos Investigar la ocurrencia de infección por el virus influenza en casos de parotiditis en una población de Santa Fe, durante 2017 y analizar las características clínicas y epidemiológicas de los casos. Materiales y Métodos: Se estudiaron pacientes con diagnóstico de parotiditis, que acudieron a la consulta desde la semana 26 en la red de médicos que forman la Unidad Centinela de Influenza en Santa Fe. Resultados: Entre las semanas epidemiológicas 26 y 44, se incluyeron 22 casos de parotiditis clínica. El virus influenza se detectó en 68,2%, influenza A (H3N2) 93% e influenza B 7%. Los síntomas clínicos de los casos fueron leves, con una tumefacción de cinco días y sin complicaciones. El 74% presentó una enfermedad tipo influenza en conjunto con la parotiditis. Conclusiones: Este estudio evidencia que niños que presentaban parotiditis tenían una infección por el virus de la influenza A (H3N2). Es necesario implementar una vigilancia sistemática de las parotiditis asociadas con influenza y el diagnóstico diferencial, incluso en ausencia de síntomas respiratorios.

Background: Parotitis is an acute viral disease characterized by swelling and pain in one or both salivary glands, submaxillary or submental, fever, headache, muscle ache and/or fatigue. Aim: To investigate the occurrence of influenza virus infection in parotitis cases in a population of Santa Fe during 2017 and analyze clinical and epidemiological characteristics of the cases. Methods: We studied patients with diagnosis of mumps without age restriction, who came for examination from week 26 to the network of clinicians forming the Sentinel Influenza Unit in Santa Fe. Results: Between epidemiological weeks 26 and 44, 22 clinical parotitis cases we enrolled. The influenza virus was detected in 68.2%, influenza A (H3N2) 93%, and influenza B, 7%. The clinical signs of cases were mild, with an average swelling development of 5 days and no complications. 74% presented with influenza-like illness in tandem with parotitis. Conclusions: This study provides evidence that a proportion of children presenting with parotitis had influenza A(H3N2) virus infection. It is necessary to implement systematic surveillance of parotitis associated with influenza and differential diagnosis even in the absence of respiratory symptoms.

Características de los casos graves de influenza en la provincia de Santa Fe durante el año 2016 / Characteristics of severe influenza cases in Santa Fe province during the year 2016

Introducción: La infección por influenza puede conllevar a graves compli-caciones, y poner en riesgo la vida. El objetivo de este trabajo fue des-cribir las características de los casos graves confirmados de influenza en la Provincia de Santa Fe durante el año 2016. Materiales y métodos: Descripción epidemiológica a partir de los datos de las fichas individuales ETI (enfermedades tipo influenza) de los casos de síndrome gripal atendidos en los servicios de salud de la provincia. Resultados: De un total de 211 casos graves confirmados, 63 fallecie-ron. El subtipo viral detectado con mayor frecuencia fue influenza A H1N1 (87,67 %). La mayor letalidad se produjo entre los mayores de 65 años (57,58 %). La chance de morir fue 2,7 veces mayor en los ca-sos en los que la administración del antiviral se demoró más de 48 horas de iniciados los síntomas (IC: 1,01-7,40; P < 0,05). Los facto-res de riesgo con mayor prevalencia fueron: EPOC (28,48 %), edad me-nor de 5 años y pacientes obesidad (23,84 %). La chance de morir fue 2,4 mayor en aquellos que presentaban al menos un factor de riesgo(OR: 2,397; 1,119-5,132; p < 0,05). De 22 vacunados, 4 fallecieron (18,18 %), todos con algún factor de riesgo asociado, mientras que de 148 no-vacunados, 50 fallecieron (33,78 %), 40 con al menos algún factor de riesgo asociado. Conclusión: La información epidemiológica recaba-da es importante para organizar y priorizar los re-cursos de salud de manera eficiente, principalmen-te en aquellos grupos en los que la gravedad de la enfermedad puede llevar a la muerte

ntroduction: Influenza infection can lead to serious complications and put life at risk. The objective of this work was to describe the characteristics of the severe cases of influenza in Santa Fe province during the year 2016. Materials and methods: An epidemiological description of severe cases of influenza was conducted based on data from the individual ETI (influenza-like-Diseases) files of the cases of influenza syndrome treated in the health services of the province. Results: Of a total of 211 confirmed severe cases, 63 died. The most frequently detected viral subtype was influenza AH1N1 (87.67%). The highest lethality occurred among those patients over 65 years old (57.58%). The chance of dying was 2.7 times higher in cases in which the administration of the antiviral was delayed for more than 48 hours after initiation of symptoms (CI: 1.01-7.40, P <0.05). The most prevalent risk factors were COPD (28.48%), age under 5 years and patients with obesity (23.84%). The chance of dying was 2.4 higher in those who had at least one risk factor (OR: 2.377, 1.119-5.132, p <0.05). Of 22 vaccinated patients, 4 died (18.18%), all had some associated risk factor. Of 148 non-vaccinated patients, 50 died (33.78%), 40 with at least one associated risk factor. Conclusion: The epidemiological information collected is important to organize and prioritize health resources efficiently, especially in those groups where the severity of the disease can lead to death

Single-dose Universal Hepatitis A Immunization in One-year-old Children in Argentina: High Prevalence of Protective Antibodies up to 9 Years After Vaccination.

BACKGROUND: Single-dose hepatitis A virus (HAV) vaccination was implemented in all Argentinean children 12 months of age in 2005. Previous studies demonstrated high prevalence of protective antibody response 4 years after single-dose vaccination. This study assessed long-term seroprotection against HAV after vaccination. METHODS: Children who received 1 dose of HAV vaccine at 1 year of age at least 6 years before enrollment were included at 5 centers in Argentina between 2013 and 2014. Demographic and socioeconomic characteristics were collected through a questionnaire. Blood samples were tested for anti-HAV antibodies. Antibody values ≥10 mIU/mL were considered seroprotective. Logistic regression analysis was performed to evaluate the association between demographic and socioeconomic variables and seroprotection. RESULTS: A total of 1088 children were included, with a median postvaccination interval of 7.7 years (range 6.3-9.2 years). Of these children, 97.4% (95% confidence interval: 96.3%-98.3%) had protective antibodies against HAV. No association between demographic or socioeconomic variables and seroprotection was found. Geometric mean concentration of antibody levels against HAV was 170.5 mUI/mL (95% confidence interval: 163.2-178.2 mUI/mL). CONCLUSIONS: Single-dose universal hepatitis A immunization in 1-year-old children resulted in sustained immunologic protection for up to 9 years in Argentina. These findings, along with the low current disease burden, confirm the success of the intervention.

Cost of Bordetella pertussis illness in tertiary hospitals in Argentina.

UNLABELLED: The National Immunization Commission and the National Program for the Control of Vaccine-Preventable Diseases (Programa Nacional de Control de Enfermedades Inmunoprevenibles, ProNaCEI) updated the immunization policy in relation to Bordetella pertussis (BP) in 2009 in order to improve the control of this disease in accordance with international recommendations. To evaluate the financial impact of this new immunization policy, we must first know the cost on the health system of having a hospitalized or outpatient child infected with BP. The objective of this study was to describe the profile of costs of hospitalized or outpatient children with laboratory-confirmed BP infection in three hospitals of Argentina. This was a prospective study of the cost of BP in the period between December 2010 and March 2012. RESULTS: The total cost for the entire cohort was 1,170,663.32 ARS (236,497.64 USD); direct medical costs were 1,124,052.31 ARS (227,081.27 USD); indirect costs and out-of-pocket expenses were 46,611 ARS (9416.6 USD). From this data, it is possible to conclude that the total average cost per patient was 10 546.52 ARS (95% CI: 9009-13,840) (2130.60 USD, 95% CI: 1820-2795), the direct medical cost per patient was 10 126.6 ARS (95% CI: 8607-13,171) (2045.77 USD, 95% CI: 1738-2660), and the indirect plus out-of-pocket costs (transportation and extras) were 419.92 ARS (95% CI: 344.7-565.3) (84 USD, 95% CI: 69-115). CONCLUSION: The cost of a hospitalized child with confirmed BP is 10,546.52 ARS (95% CI: 9009-13,840) (2130.60 USD, 95% CI: 1820-2795). Direct non-medical costs and overhead costs account for 4% of the total cost, amounting to 419.91 ARS per family (84 USD, 95% CI: 69-115), approximately an 8% of an average salary.

Costos de la enfermedad por Bordetella pertussis en hospitales terciarios de la Argentina / Cost of Bordetella pertussis illness in tertiary hospitals in Argentina

La Comisión Nacional de Inmunizaciones y el ProNaCEI (Programa Nacional de Control de Enfermedades Inmunoprevenibles) actualizaron la política de vacunación por Bordetella pertussis (BP) a partir del año 2009 con el objetivo de optimizar el control de esta enfermedad, de acuerdo con las recomendaciones internacionales. Para evaluar el impacto económico de esta nueva política de vacunación resulta necesario conocer inicialmente el costo que implica para el sistema de salud un niño internado o ambulatorio con infección por BP. El objetivo de este estudio fue describir el perfl de costos en niños internados o tratados ambulatoriamente, con infección confrmada por laboratorio de BP en tres hospitales de la Argentina. Estudio prospectivo de costo de la enfermedad durante el período diciembre de 2010 a marzo de 2012. Resultados. El costo total para toda la cohorte fue de 1 170 663,32 pesos (236 497,64 dólares); los costos médicos directos, de 1 124 052,31 pesos (227 081,27 dólares); los costos indirectos y gastos de bolsillo, de 46611 pesos (9 416,36 dólares), lo que permite inferir un costo total promedio por paciente de 10 546,52 pesos (IC 95% 9009 a 13 840) (2130,60 dólares, IC 95% 1820 a 2795), costos médicos directos por paciente de 10 126,6 pesos (IC 95% 8607 a 13 171) (2045,77 dólares, IC 95%1738 a 2660) y costos indirectos más de bolsillo (viajes y extras) de 419,92 pesos (IC 95% 344,7 a 565,3), (84 dólares, IC 95% 69 a 115). Conclusión. El costo de un caso confrmado hospitalizado por BP es 10 546,52 pesos (IC 95% 9009 a 13 840) (2130,60 dólares, IC 95% 1820 a 2795). Los costos directos no médicos y costos indirectos constituyen el 4% del total, lo que corresponde a 419,91 pesos por familia (84 dólares, IC 95% 69 a 115), un 8% del salario promedio.

The National Immunization Commission and the National Program for the Control of Vaccine-Preventable Diseases (Programa Nacional de Control de Enfermedades Inmunoprevenibles, ProNaCEI) updated the immunization policy in relation to Bordetella pertussis (BP) in 2009 in order to improve the control of this disease in accordance with international recommendations. To evaluate the fnancial impact of this new immunization policy, we must frst know the cost on the health system of having a hospitalized or outpatient child infected with BP. The objective of this study was to describe the profle of costs of hospitalized or outpatient children with laboratory-confrmed BP infection in three hospitals of Argentina. This was a prospective study of the cost of BP in the period between December 2010 and March 2012. Results. The total cost for the entire cohort was 1 170 663.32 ARS (236 497.64 USD); direct medical costs were 1 124 052.31 ARS (227 081.27 USD); indirect costs and out-of-pocket expenses were 46 611 ARS (9416.6 USD). From this data, it is possible to conclude that the total average cost per patient was 10 546.52 ARS (95% CI: 9009-13 840) (2130.60 USD, 95% CI: 1820-2795), the direct medical cost per patient was 10 126.6 ARS (95% CI: 8607-13 171) (2045.77 USD, 95% CI: 1738-2660), and the indirect plus out-of-pocket costs (transportation and extras) were 419.92 ARS (95% CI: 344.7-565.3) (84 USD, 95% CI: 69-115). Conclusion. The cost of a hospitalized child with confrmed BP is 10 546.52 ARS (95% CI: 9009-13 840) (2130.60 USD, 95% CI: 1820-2795). Direct non-medical costs and overhead costs account for 4% of the total cost, amounting to 419.91 ARS per family (84 USD, 95% CI: 69-115), approximately an 8% of an average salary.

Costos de la enfermedad por Bordetella pertussis en hospitales terciarios de la Argentina / Cost of Bordetella pertussis illness in tertiary hospitals in Argentina

La Comisión Nacional de Inmunizaciones y el ProNaCEI (Programa Nacional de Control de Enfermedades Inmunoprevenibles) actualizaron la política de vacunación por Bordetella pertussis (BP) a partir del año 2009 con el objetivo de optimizar el control de esta enfermedad, de acuerdo con las recomendaciones internacionales. Para evaluar el impacto económico de esta nueva política de vacunación resulta necesario conocer inicialmente el costo que implica para el sistema de salud un niño internado o ambulatorio con infección por BP. El objetivo de este estudio fue describir el perfl de costos en niños internados o tratados ambulatoriamente, con infección confrmada por laboratorio de BP en tres hospitales de la Argentina. Estudio prospectivo de costo de la enfermedad durante el período diciembre de 2010 a marzo de 2012. Resultados. El costo total para toda la cohorte fue de 1 170 663,32 pesos (236 497,64 dólares); los costos médicos directos, de 1 124 052,31 pesos (227 081,27 dólares); los costos indirectos y gastos de bolsillo, de 46611 pesos (9 416,36 dólares), lo que permite inferir un costo total promedio por paciente de 10 546,52 pesos (IC 95% 9009 a 13 840) (2130,60 dólares, IC 95% 1820 a 2795), costos médicos directos por paciente de 10 126,6 pesos (IC 95% 8607 a 13 171) (2045,77 dólares, IC 95%1738 a 2660) y costos indirectos más de bolsillo (viajes y extras) de 419,92 pesos (IC 95% 344,7 a 565,3), (84 dólares, IC 95% 69 a 115). Conclusión. El costo de un caso confrmado hospitalizado por BP es 10 546,52 pesos (IC 95% 9009 a 13 840) (2130,60 dólares, IC 95% 1820 a 2795). Los costos directos no médicos y costos indirectos constituyen el 4% del total, lo que corresponde a 419,91 pesos por familia (84 dólares, IC 95% 69 a 115), un 8% del salario promedio.(AU)

The National Immunization Commission and the National Program for the Control of Vaccine-Preventable Diseases (Programa Nacional de Control de Enfermedades Inmunoprevenibles, ProNaCEI) updated the immunization policy in relation to Bordetella pertussis (BP) in 2009 in order to improve the control of this disease in accordance with international recommendations. To evaluate the fnancial impact of this new immunization policy, we must frst know the cost on the health system of having a hospitalized or outpatient child infected with BP. The objective of this study was to describe the profle of costs of hospitalized or outpatient children with laboratory-confrmed BP infection in three hospitals of Argentina. This was a prospective study of the cost of BP in the period between December 2010 and March 2012. Results. The total cost for the entire cohort was 1 170 663.32 ARS (236 497.64 USD); direct medical costs were 1 124 052.31 ARS (227 081.27 USD); indirect costs and out-of-pocket expenses were 46 611 ARS (9416.6 USD). From this data, it is possible to conclude that the total average cost per patient was 10 546.52 ARS (95% CI: 9009-13 840) (2130.60 USD, 95% CI: 1820-2795), the direct medical cost per patient was 10 126.6 ARS (95% CI: 8607-13 171) (2045.77 USD, 95% CI: 1738-2660), and the indirect plus out-of-pocket costs (transportation and extras) were 419.92 ARS (95% CI: 344.7-565.3) (84 USD, 95% CI: 69-115). Conclusion. The cost of a hospitalized child with confrmed BP is 10 546.52 ARS (95% CI: 9009-13 840) (2130.60 USD, 95% CI: 1820-2795). Direct non-medical costs and overhead costs account for 4% of the total cost, amounting to 419.91 ARS per family (84 USD, 95% CI: 69-115), approximately an 8% of an average salary.(AU)

Clinical features of the hospitalized patients with 2009 pandemic influenza A (H1N1) in Santa Fe, Argentina.

BACKGROUND: During 2009 occurred the emergence and global spread of a novel influenza A (H1N1) virus. We describe the clinical and epidemiologic features of hospitalized patients who survived and patients who died because of pandemic 2009 influenza A (H1N1) infection reported in Santa Fe, Argentina, from May to July 2009. METHODS: Using medical charts, we collected data on 242 patients who were hospitalized with confirmed laboratory results (defined as positive by specific PCR for pandemic 2009 influenza A H1N1). RESULTS: During the study period, there were 242 cases of hospitalization or death. Of the 242, 46% were admitted to an intensive care unit (ICU) and 33·5% died. The mean age was 27·8 years for surviving and 39·6 for those who died. Twenty-eight percent of hospitalizations involved persons under the age of 15 years; 33% of the patients were between the age of 15 and 44 years; and only 3·3% were 65 years of age or older. Sixty-seven percent had an underlying medical conditions, including diabetes, obesity, heart and lung diseases, and pregnancy. Of the 242 patients, 68% had findings consistent with pneumonia. Treatment with oseltamivir was administered to 227 (93·8%) patients from which 38 received oseltamivir within 48 hours after the onset of symptoms. CONCLUSIONS: The pandemic strain caused severe illness, including pneumonia and acute respiratory distress syndrome, and resulted in ICU admissions in 46% of patients and death in 33·5%. The mean age of hospitalized infected cases was lower than is common with seasonal influenza. Underlying medical conditions were common in the 67% the evaluated patients. Patients who died had a higher prevalence of comorbidities (86·4%) than those who survived (57%), suggesting that the presence of chronic illness may increase the likelihood of death. However, the severe illness was also identified among young, healthy persons.

Cost of Bordetella pertussis illness in tertiary hospitals in Argentina. / Cost of Bordetella pertussis illness in tertiary hospitals in Argentina.

UNLABELLED: The National Immunization Commission and the National Program for the Control of Vaccine-Preventable Diseases (Programa Nacional de Control de Enfermedades Inmunoprevenibles, ProNaCEI) updated the immunization policy in relation to Bordetella pertussis (BP) in 2009 in order to improve the control of this disease in accordance with international recommendations. To evaluate the financial impact of this new immunization policy, we must first know the cost on the health system of having a hospitalized or outpatient child infected with BP. The objective of this study was to describe the profile of costs of hospitalized or outpatient children with laboratory-confirmed BP infection in three hospitals of Argentina. This was a prospective study of the cost of BP in the period between December 2010 and March 2012. RESULTS: The total cost for the entire cohort was 1,170,663.32 ARS (236,497.64 USD); direct medical costs were 1,124,052.31 ARS (227,081.27 USD); indirect costs and out-of-pocket expenses were 46,611 ARS (9416.6 USD). From this data, it is possible to conclude that the total average cost per patient was 10 546.52 ARS (95

CI: 9009-13,840) (2130.60 USD, 95

CI: 1820-2795), the direct medical cost per patient was 10 126.6 ARS (95

CI: 8607-13,171) (2045.77 USD, 95

CI: 1738-2660), and the indirect plus out-of-pocket costs (transportation and extras) were 419.92 ARS (95

CI: 344.7-565.3) (84 USD, 95

CI: 69-115). CONCLUSION: The cost of a hospitalized child with confirmed BP is 10,546.52 ARS (95

CI: 9009-13,840) (2130.60 USD, 95

CI: 1820-2795). Direct non-medical costs and overhead costs account for 4

of the total cost, amounting to 419.91 ARS per family (84 USD, 95

CI: 69-115), approximately an 8

of an average salary.

Mortality, severe acute respiratory infection, and influenza-like illness associated with influenza A(H1N1)pdm09 in Argentina, 2009.

INTRODUCTION: While there is much information about the burden of influenza A(H1N1)pdm09 in North America, little data exist on its burden in South America. METHODS: During April to December 2009, we actively searched for persons with severe acute respiratory infection and influenza-like illness (ILI) in three sentinel cities. A proportion of case-patients provided swabs for influenza testing. We estimated the number of case-patients that would have tested positive for influenza by multiplying the number of untested case-patients by the proportion who tested positive. We estimated rates by dividing the estimated number of case-patients by the census population after adjusting for the proportion of case-patients with missing illness onset information and ILI case-patients who visited physicians multiple times for one illness event. RESULTS: We estimated that the influenza A(H1N1)pdm09 mortality rate per 100,000 person-years (py) ranged from 1.5 among persons aged 5-44 years to 5.6 among persons aged ≥ 65 years. A(H1N1)pdm09 hospitalization rates per 100,000 py ranged between 26.9 among children aged <5 years to 41.8 among persons aged ≥ 65 years. Influenza A(H1N1)pdm09 ILI rates per 100 py ranged between 1.6 among children aged <5 to 17.1 among persons aged 45-64 years. While 9 (53%) of 17 influenza A(H1N1)pdm09 decedents with available data had obesity and 7 (17%) of 40 had diabetes, less than 4% of surviving influenza A(H1N1)pdm09 case-patients had these pre-existing conditions (p ≤ 0.001). CONCLUSION: Influenza A(H1N1)pdm09 caused a similar burden of disease in Argentina as in other countries. Such disease burden suggests the potential value of timely influenza vaccinations.

Lactancia y transmisión madre-hijo del VIH en niños nacidos en las Maternidades Municipales de Rosario de 1999 a 2010 / Breastfeeding and mother-child transmission of HIV in infants born in maternity hospitals of Rosario Municipal 1999 to 2010

Se revisaron los casos de infección por VIH-1 ocurridos entre niños nacidos en maternidades municipales de Rosario, de 1999 a 2010 notificados al 30 de noviembre de 2011 para identificar el rol jugado por la lactancia materna. Se hallaron 12 casos entre 71.283 partos, de los cuales 479 fueron parturientas VIH positivas. hubo 6 mujeres con serología/s negativas previas o al momento del parto, diagnosticadas como VIH positivas meintras amamantaban sus hijos que resultaron infectados. Se proponen criterios para definir la posibilidad de la asociación. Nombramos estas madres como seroconvertidoras al VIH perinatales con diagnóstico intralactancia. Diez casos mostraron asociación con uso de drogas. La Tasa de Transmisión Vertical hallada fue 2,47 %, y podría reducirse aún más con el diagnóstico de VIH precoz durante la lactancia materna. Proponemos comunicar este problema y promover pruebas de VIH asesoradas ofrecidas regularmente desde los servicios a mujeres que amamantan y sus parejas.

Lactancia y transmisión madre-hijo del VIH en niños nacidos en las Maternidades Municipales de Rosario de 1999 a 2010 / Breastfeeding and mother-child transmission of HIV in infants born in maternity hospitals of Rosario Municipal 1999 to 2010

Se revisaron los casos de infección por VIH-1 ocurridos entre niños nacidos en maternidades municipales de Rosario, de 1999 a 2010 notificados al 30 de noviembre de 2011 para identificar el rol jugado por la lactancia materna. Se hallaron 12 casos entre 71.283 partos, de los cuales 479 fueron parturientas VIH positivas. hubo 6 mujeres con serología/s negativas previas o al momento del parto, diagnosticadas como VIH positivas meintras amamantaban sus hijos que resultaron infectados. Se proponen criterios para definir la posibilidad de la asociación. Nombramos estas madres como seroconvertidoras al VIH perinatales con diagnóstico intralactancia. Diez casos mostraron asociación con uso de drogas. La Tasa de Transmisión Vertical hallada fue 2,47 %, y podría reducirse aún más con el diagnóstico de VIH precoz durante la lactancia materna. Proponemos comunicar este problema y promover pruebas de VIH asesoradas ofrecidas regularmente desde los servicios a mujeres que amamantan y sus parejas.(AU)

Lactancia y transmisión madre-hijo del VIH en niños nacidos en las Maternidades Municipales de Rosario de 1999 a 2010 / Breastfeeding and mother-child transmission of HIV in infants born in maternity hospitals of Rosario Municipal 1999 to 2010

Se revisaron los casos de infección por VIH-1 ocurridos entre niños nacidos en maternidades municipales de Rosario, de 1999 a 2010 notificados al 30 de noviembre de 2011 para identificar el rol jugado por la lactancia materna. Se hallaron 12 casos entre 71.283 partos, de los cuales 479 fueron parturientas VIH positivas. hubo 6 mujeres con serología/s negativas previas o al momento del parto, diagnosticadas como VIH positivas meintras amamantaban sus hijos que resultaron infectados. Se proponen criterios para definir la posibilidad de la asociación. Nombramos estas madres como seroconvertidoras al VIH perinatales con diagnóstico intralactancia. Diez casos mostraron asociación con uso de drogas. La Tasa de Transmisión Vertical hallada fue 2,47 %, y podría reducirse aún más con el diagnóstico de VIH precoz durante la lactancia materna. Proponemos comunicar este problema y promover pruebas de VIH asesoradas ofrecidas regularmente desde los servicios a mujeres que amamantan y sus parejas.(AU)